CN101234102A - 一种盐酸椒苯酮胺冻干粉针剂及其制备方法和用途 - Google Patents
一种盐酸椒苯酮胺冻干粉针剂及其制备方法和用途 Download PDFInfo
- Publication number
- CN101234102A CN101234102A CNA2007100032356A CN200710003235A CN101234102A CN 101234102 A CN101234102 A CN 101234102A CN A2007100032356 A CNA2007100032356 A CN A2007100032356A CN 200710003235 A CN200710003235 A CN 200710003235A CN 101234102 A CN101234102 A CN 101234102A
- Authority
- CN
- China
- Prior art keywords
- injection
- freeze
- warmed
- excipient
- peperphentonamine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 46
- 239000007924 injection Substances 0.000 title claims abstract description 46
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims description 129
- 238000002360 preparation method Methods 0.000 title abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 74
- 239000008215 water for injection Substances 0.000 claims abstract description 72
- 238000001035 drying Methods 0.000 claims abstract description 58
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 52
- 206010019280 Heart failures Diseases 0.000 claims abstract description 32
- 230000002107 myocardial effect Effects 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 16
- 229930195725 Mannitol Natural products 0.000 claims abstract description 16
- 239000000594 mannitol Substances 0.000 claims abstract description 16
- 235000010355 mannitol Nutrition 0.000 claims abstract description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 9
- 239000008101 lactose Substances 0.000 claims abstract description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920001983 poloxamer Polymers 0.000 claims abstract description 7
- 229960000502 poloxamer Drugs 0.000 claims abstract description 7
- 229920002307 Dextran Polymers 0.000 claims abstract description 6
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 59
- 238000012856 packing Methods 0.000 claims description 38
- 238000001914 filtration Methods 0.000 claims description 35
- 238000005303 weighing Methods 0.000 claims description 33
- 230000001954 sterilising effect Effects 0.000 claims description 31
- 238000004659 sterilization and disinfection Methods 0.000 claims description 31
- 238000000859 sublimation Methods 0.000 claims description 30
- 230000008022 sublimation Effects 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 24
- 238000004108 freeze drying Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 5
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims 2
- 238000003825 pressing Methods 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 6
- 238000007710 freezing Methods 0.000 abstract description 5
- 230000008014 freezing Effects 0.000 abstract description 3
- 239000011521 glass Substances 0.000 abstract 1
- 235000015110 jellies Nutrition 0.000 abstract 1
- 239000008274 jelly Substances 0.000 abstract 1
- 229920000151 polyglycol Polymers 0.000 abstract 1
- 239000010695 polyglycol Substances 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 89
- 239000002994 raw material Substances 0.000 description 74
- 206010013786 Dry skin Diseases 0.000 description 52
- 230000008569 process Effects 0.000 description 34
- 239000011575 calcium Substances 0.000 description 32
- 229910000831 Steel Inorganic materials 0.000 description 29
- 239000010959 steel Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 25
- 238000002156 mixing Methods 0.000 description 21
- 229910052791 calcium Inorganic materials 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 15
- 241000282326 Felis catus Species 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 10
- 238000005352 clarification Methods 0.000 description 10
- 230000008602 contraction Effects 0.000 description 10
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 229960001722 verapamil Drugs 0.000 description 8
- 206010063837 Reperfusion injury Diseases 0.000 description 7
- 230000004217 heart function Effects 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004257 Potassium Channel Human genes 0.000 description 6
- NYQCKFLLTCINSJ-UHFFFAOYSA-N hydron;3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1h-pyridazin-6-one;chloride Chemical compound Cl.N1C(=O)CCC(C=2C=CC(NC=3C=CN=CC=3)=CC=2)=N1 NYQCKFLLTCINSJ-UHFFFAOYSA-N 0.000 description 6
- 108020001213 potassium channel Proteins 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- ALSPKRWQCLSJLV-UHFFFAOYSA-N azanium;acetic acid;acetate Chemical compound [NH4+].CC(O)=O.CC([O-])=O ALSPKRWQCLSJLV-UHFFFAOYSA-N 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000003680 myocardial damage Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 229940122434 Calcium sensitizer Drugs 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 4
- 229960003574 milrinone Drugs 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 229920003366 poly(p-phenylene terephthalamide) Polymers 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 3
- 102000013394 Troponin I Human genes 0.000 description 3
- 108010065729 Troponin I Proteins 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 241001411320 Eriogonum inflatum Species 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical class C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 2
- 229960000692 levosimendan Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- FHUOTRMCFQTSOA-UHFFFAOYSA-M potassium;acetic acid;acetate Chemical compound [K+].CC(O)=O.CC([O-])=O FHUOTRMCFQTSOA-UHFFFAOYSA-M 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- XMFCOYRWYYXZMY-UHFFFAOYSA-N sulmazole Chemical compound COC1=CC(S(C)=O)=CC=C1C1=NC2=NC=CC=C2N1 XMFCOYRWYYXZMY-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- JEJGJJSMKOHPTP-XBXARRHUSA-N (E)-5-[2-(1,3-benzodioxol-5-yl)ethyl-methylamino]-1-(4-hydroxyphenyl)pent-1-en-3-one Chemical compound C=1C=C2OCOC2=CC=1CCN(C)CCC(=O)\C=C\C1=CC=C(O)C=C1 JEJGJJSMKOHPTP-XBXARRHUSA-N 0.000 description 1
- MXVIFUCWSSCOCK-ZFXMFRGYSA-N (E)-5-[2-(1,3-benzodioxol-5-yl)ethyl-methylamino]-1-(4-hydroxyphenyl)pent-1-en-3-one hydrochloride Chemical compound Cl.C=1C=C2OCOC2=CC=1CCN(C)CCC(=O)\C=C\C1=CC=C(O)C=C1 MXVIFUCWSSCOCK-ZFXMFRGYSA-N 0.000 description 1
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229940122117 Potassium channel agonist Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- CSVGEMRSDNSWRF-UHFFFAOYSA-L disodium;dihydrogen phosphate Chemical compound [Na+].[Na+].OP(O)([O-])=O.OP(O)([O-])=O CSVGEMRSDNSWRF-UHFFFAOYSA-L 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- LRWJZGCOPMDWFZ-UHFFFAOYSA-N phthalic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1C(O)=O LRWJZGCOPMDWFZ-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229950006153 sulmazole Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
时间 | 外观性状 | 溶液的颜色 | 澄清度 | pH值 | 水分% | 分解产生杂质 | 标示含量 |
0天 | 白色冻干粉末 | 溶液颜色与YG1相当 | 符合规定 | 2.0-5.5 | 1.0-4.0 | 单个<1.0%总量<2.0% | 103.8%104.2% |
1个月 | 白色冻干粉末 | 溶液颜色与YG1相当 | 符合规定 | 2.0-5.5 | 1.0-4.0 | 单个<1.0%总量<2.0% | 103.9%102.5% |
2个月 | 自色冻干粉末 | YG1-YG2之间 | 符合规定 | 2.0-5.5 | 1.0-4.0 | 单个<1.0%总量<2.0% | 104.0%103.4% |
3个月 | 白色冻干粉末 | YG1-YG2之间 | 符合规定 | 2.0-5.5 | 1.0-4.0 | 单个<1.0%总量<2.0% | 101.6%101.7% |
6个月 | 白色冻于粉末 | 在YG1-YG2之间 | 符合规定 | 2.0-5.5 | 1.0-4.0 | 单个<1.0%总量<2.0% | 102.7%104.1% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100032356A CN101234102B (zh) | 2007-01-31 | 2007-01-31 | 一种盐酸椒苯酮胺冻干粉针剂及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100032356A CN101234102B (zh) | 2007-01-31 | 2007-01-31 | 一种盐酸椒苯酮胺冻干粉针剂及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101234102A true CN101234102A (zh) | 2008-08-06 |
CN101234102B CN101234102B (zh) | 2010-08-18 |
Family
ID=39918169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100032356A Expired - Fee Related CN101234102B (zh) | 2007-01-31 | 2007-01-31 | 一种盐酸椒苯酮胺冻干粉针剂及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101234102B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011035500A1 (zh) * | 2009-09-24 | 2011-03-31 | 广州市众为生物技术有限公司 | 椒苯酮胺或其盐在制备预防/治疗脑病的药物中的用途 |
CN105597569A (zh) * | 2016-01-18 | 2016-05-25 | 天津工业大学 | 一种增强型聚间苯二甲酰间苯二胺中空纤维膜的制备方法 |
CN106389350A (zh) * | 2015-07-30 | 2017-02-15 | 重庆东泽医药科技发展有限公司 | 一种注射用的左旋奥拉西坦无菌粉末及其制备方法 |
CN106955272A (zh) * | 2016-03-31 | 2017-07-18 | 重庆润泽医药有限公司 | 一种注射用的左旋奥拉西坦无菌粉末及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1205928C (zh) * | 2002-07-24 | 2005-06-15 | 广州市众为生物技术有限公司 | 椒苯酮胺或其盐用作制备治疗心血管疾病药物的应用 |
-
2007
- 2007-01-31 CN CN2007100032356A patent/CN101234102B/zh not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011035500A1 (zh) * | 2009-09-24 | 2011-03-31 | 广州市众为生物技术有限公司 | 椒苯酮胺或其盐在制备预防/治疗脑病的药物中的用途 |
CN102028681B (zh) * | 2009-09-24 | 2012-05-30 | 广州市众为生物技术有限公司 | 椒苯酮胺或其盐在制备预防/治疗脑病的药物中的用途 |
US8916607B2 (en) | 2009-09-24 | 2014-12-23 | Guangzhou Municipal Zhongwei Biotechnology Limited Company | Use of piperphentonamine or salts thereof in manufacture of medicaments for treating brain diseases |
CN106389350A (zh) * | 2015-07-30 | 2017-02-15 | 重庆东泽医药科技发展有限公司 | 一种注射用的左旋奥拉西坦无菌粉末及其制备方法 |
CN105597569A (zh) * | 2016-01-18 | 2016-05-25 | 天津工业大学 | 一种增强型聚间苯二甲酰间苯二胺中空纤维膜的制备方法 |
CN105597569B (zh) * | 2016-01-18 | 2019-01-25 | 天津工业大学 | 一种增强型聚间苯二甲酰间苯二胺中空纤维膜的制备方法 |
CN106955272A (zh) * | 2016-03-31 | 2017-07-18 | 重庆润泽医药有限公司 | 一种注射用的左旋奥拉西坦无菌粉末及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101234102B (zh) | 2010-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
KR100917809B1 (ko) | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 | |
Gu et al. | Effects of Chinese herb medicine Radix Scrophulariae on ventricular remodeling | |
US11351184B2 (en) | Preparation of Pulsatilla saponin B4 for injection | |
CN101234102B (zh) | 一种盐酸椒苯酮胺冻干粉针剂及其制备方法和用途 | |
CN100998552A (zh) | 一种用于口服制剂的药物组合物及其制备方法 | |
CA3049703A1 (en) | New use of a long-acting mutant human fibroblast growth factor | |
CN1847243A (zh) | 一种新的伏立康唑可溶性盐的制备方法及其制剂 | |
WO2008119260A1 (fr) | Composition médicinale de carmustine, procédé de préparation et application | |
CN102416001B (zh) | 一种注射用醋酸奥曲肽冻干粉针剂及其制备方法 | |
CN101317846B (zh) | 一种用于戒毒、镇痛的河豚毒素制剂 | |
US8513301B2 (en) | Kind of piperphentonamine hydrochloride lyophilized powder for injection and preparation and use thereof | |
CN104940181B (zh) | β‑羟丁酸或其药学上可接受的盐的用途 | |
CN101891751B (zh) | 一种河豚毒素的制备方法 | |
CN103183722A (zh) | 一种乙二醛酶ⅰ抑制剂及其制备方法和医药用途 | |
CN100496506C (zh) | 葛根素注射用制剂 | |
CN112007058A (zh) | 木蝴蝶作为抗氧化应激损伤剂的应用 | |
CN101804034B (zh) | 一种雷贝拉唑钠粉针剂及其制备方法 | |
CN1686140A (zh) | 盐酸伐昔洛韦冻干制剂及其制备方法 | |
CN109288824A (zh) | 一种保肝药物组合物 | |
CN1234363C (zh) | 含有右雷佐生的冻干组合物及其制备方法 | |
CN102796156B (zh) | 环磷腺苷二葡甲胺化合物及其制备方法 | |
CN110652498B (zh) | 一种用于治疗2型糖尿病的药物制剂及其制备方法 | |
CN100462072C (zh) | 一种用于注射制剂的药物组合物及其制备方法 | |
CN101297802A (zh) | 水飞蓟宾二偏琥珀酸酯氧化苦参碱复盐及苦参碱复盐的制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUXI JIMIN KEXIN SHANHE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHONGWEI BIOTECHNOLOGY CO LTD, GUANGZHOU CITY Effective date: 20140121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510633 GUANGZHOU, GUANGDONG PROVINCE TO: 214000 WUXI, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140121 Address after: 214000 No. 12 Changjiang Road, New District, Jiangsu, Wuxi Patentee after: WUXI JIMIN KEXIN SHANHE PHARMACEUTICAL Co.,Ltd. Address before: 510633 E413 room, international business incubator, Daguan Road, Guangzhou Science City, Guangdong Patentee before: GUANGZHOU MUNICIPAL ZHONGWEI BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 214028 Changjiang South Road, new Wu District, Wuxi, Jiangsu Province, No. 12 Patentee after: Wuxi Jiyu Shanhe Pharmaceutical Co.,Ltd. Address before: No.12, Changjiang Road, New District, Wuxi, Jiangsu Province Patentee before: WUXI JIMIN KEXIN SHANHE PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211210 Address after: 330052 No. 1, hEPO Road, Xiaolan economic and Technological Development Zone, Nanchang City, Jiangxi Province Patentee after: Jiangxi Guoneng Pharmaceutical Technology Co.,Ltd. Address before: No.12, South Changjiang Road, Xinwu District, Wuxi City, Jiangsu Province Patentee before: Wuxi Jiyu Shanhe Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100818 |
|
CF01 | Termination of patent right due to non-payment of annual fee |